Emerging studies suggest Retatrutide , a dual activator targeting both incretin and another hormone, appears to represent a significant advancement for obesity loss . Preliminary human tests have shown considerable reductions in visceral fat , potentially surpassing existing body composition medications . Nevertheless , additional assessment is req